Acadia Pharmaceuticals’ schizophrenia drug fails in late-stage study

(Reuters) – Acadia Pharmaceuticals said on Monday its experimental drug to treat negative symptoms of schizophrenia failed to meet the main goal in a late-stage study.

(Reporting by Mariam Sunny in Bengaluru)